Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
Rhea-AI Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) reported Q1 2026 results and key updates on tegoprubart.
All 10 evaluable type 1 diabetes patients achieved 100% insulin independence after islet transplantation. Tegoprubart received FDA Orphan Drug designation in liver transplantation. Cash was $111.1M, funding operations into 2Q 2027; Q1 net loss was $39.0M.
AI-generated analysis. Not financial advice.
Positive
- 10 of 10 eligible islet transplant patients achieved 100% insulin independence
- No graft rejection, donor-specific antibodies, or common tacrolimus toxicities observed in islet trial
- FDA Orphan Drug designation for tegoprubart in liver transplantation
- Kidney transplant eGFR increased from 67.0 to 74.2 mL/min/1.73 m2 at 24 months
- No acute rejection, graft loss, death, or new-onset diabetes in 24‑month kidney data
- Cash, cash equivalents and short-term investments of $111.1M, runway into 2Q 2027
Negative
- Cash, cash equivalents and short-term investments declined from $133.3M to $111.1M in Q1 2026
- Q1 2026 net loss was $39.0M versus $6.5M in Q1 2025
- Non-GAAP net loss excluding warrant revaluation was $20.1M versus $16.6M year prior
- R&D expenses rose to $17.2M from $13.5M year over year
News Market Reaction – ELDN
On the day this news was published, ELDN gained 1.80%, reflecting a mild positive market reaction. This price movement added approximately $5M to the company's valuation, bringing the market cap to $304.89M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ELDN gained 2.09% while close peers were mixed: MCRB +1.66%, NKTX +3.47%, AARD +7.76%, but CABA -3.46% and NVCT -0.73%. The pattern points to a stock-specific reaction rather than a clean sector rotation.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Full-year 2025 results | Positive | +1.1% | Reported FY 2025 results with clinical progress and orphan designation for liver. |
| Nov 14 | Q3 2025 earnings | Positive | -8.0% | Q3 2025 results, BESTOW data and $57.5M raise alongside cash update. |
| Aug 14 | Q2 2025 earnings | Positive | +1.1% | Q2 2025 update with positive kidney data and $107.6M cash. |
| May 14 | Q1 2025 earnings | Positive | +2.1% | Q1 2025 results, BESTOW timeline and xenotransplant progress. |
| Mar 20 | FY 2024 earnings | Positive | +2.0% | Q4/FY 2024 results with key transplant advances and $140.2M cash. |
Earnings/news updates for ELDN have usually drawn modestly positive reactions, with one notable selloff after a 2025 Q3 update despite operational progress.
Over the last year, Eledon’s earnings releases have consistently paired financial updates with tegoprubart milestones. Prior quarters highlighted kidney transplant eGFR improvements around 67–69 mL/min/1.73m², strong islet transplant data (up to 10/10 insulin-independent patients), and cash balances ranging from $93.4M to $140.2M. The current Q1 2026 report continues this pattern, combining new transplant data, an FDA Orphan Drug designation, and a cash position of $111.1M, extending the company’s operating runway while development spending remains elevated.
Historical Comparison
Recent earnings releases often paired cash runway updates with tegoprubart milestones. Historically, same‑tag events moved the stock by an average of about -0.32%, making this reaction directionally consistent but somewhat stronger than prior norms.
Earnings updates progressed from FY 2024 through 2025 with growing tegoprubart data and evolving cash runway. This Q1 2026 release extends that narrative, adding new transplant data, an Orphan Drug designation, and updated runway guidance into 2Q 2027.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-05-01 allows Eledon to offer up to $500,000,000 in securities, including an ATM program for up to $75,000,000 of common stock. No usage has been reported yet, but the structure provides substantial capacity for future equity or debt financing.
Market Pulse Summary
This announcement combines strong tegoprubart data in kidney and islet transplantation, an FDA Orphan Drug designation in liver transplantation, and a cash balance of $111.1M expected to fund operations into 2Q 2027. Investors may compare these updates to prior earnings releases that also tied financials to clinical milestones. Key factors to watch include upcoming Phase 3 design feedback, additional long-term kidney data, and any future use of the newly effective $500M shelf and ATM program.
Key Terms
orphan drug designation regulatory
allograft rejection medical
islet transplantation medical
estimated glomerular filtration rate (eGFR) medical
phase 3 medical
phase 2 medical
phase 1b medical
tacrolimus-based immunosuppression medical
AI-generated analysis. Not financial advice.
FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation
Cash, cash equivalents and short-term investments totaled
IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2026 operating and financial results and provided recent business highlights.
“In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including important data updates in kidney and islet cell transplantation and FDA Orphan Drug designation for tegoprubart in liver transplantation,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “Looking ahead, we expect multiple catalysts in 2026, including regulatory engagements supporting the advancement of tegoprubart into Phase 3 development in kidney transplantation and discussions regarding a potential path to market in islet cell transplantation. We also plan to initiate several new clinical trials, including an investigator sponsored study in liver transplantation, and share new kidney transplant data from our Phase 2 BESTOW long-term extension study, building on encouraging 24-month Phase 1b results that demonstrated a durable safety profile and improved graft function.”
First Quarter 2026 Business Highlights
- In March 2026, announced updated results from an ongoing investigator-led trial at the University of Chicago Medicine Transplant Institute evaluating tegoprubart in 12 adults with high-risk type 1 diabetes undergoing allogenic islet transplantation. All 10 patients who are more than four weeks post-transplant achieved
100% insulin independence. There were no signs of graft rejection or de novo donor-specific HLA antibodies and no evidence of nephrotoxicity, hypertension, or neurotoxicity, which are commonly associated with tacrolimus-based immunosuppression regimens, the current standard of care. - The U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation.
- Presented 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension trial evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium in January 2026. Results showed there were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m2 at 12 months to 74.2 mL/min/1.73 m2 at 24 months.
2026 Anticipated Upcoming Milestones
- Receive FDA guidance on the Phase 3 trial design assessing tegoprubart in kidney transplantation, followed by initiation of the Phase 3 trial pending regulatory alignment.
- Report long-term data from Phase 1b and Phase 2 BESTOW studies evaluating tegoprubart in kidney transplantation.
- Receive FDA regulatory guidance on the path to market for tegoprubart in islet cell transplantation and xenotransplantation.
- Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients with renal dysfunction receiving an islet cell transplant.
- Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo liver transplant.
- Initiate an investigator-led study evaluating tegoprubart for kidney transplant tolerance induction.
First Quarter 2026 Financial Results
Cash, cash equivalents and short-term investments totaled
Research and development (R&D) expenses for the first quarter of 2026 were
General and administrative (G&A) expenses for the first quarter of 2026 were
Net loss for the first quarter of 2026 was
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; X
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain
insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
| ELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (Unaudited) | ||||||||
| March 31, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 6,152 | $ | 22,808 | ||||
| Short-term investments | 104,937 | 110,528 | ||||||
| Prepaid expenses and other current assets | 2,485 | 2,352 | ||||||
| Total current assets | 113,574 | 135,688 | ||||||
| Operating lease asset, net | 530 | 613 | ||||||
| In-process research and development | 32,386 | 32,386 | ||||||
| Other assets | 177 | 322 | ||||||
| Total assets | $ | 146,667 | $ | 169,009 | ||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 6,585 | $ | 3,627 | ||||
| Current operating lease liabilities | 369 | 358 | ||||||
| Accrued expenses and other liabilities | 6,504 | 14,359 | ||||||
| Total current liabilities | 13,458 | 18,344 | ||||||
| Deferred tax liabilities | 2,187 | 2,187 | ||||||
| Non-current operating lease liabilities | 186 | 283 | ||||||
| Warrant liabilities | 30,378 | 11,416 | ||||||
| Total liabilities | 46,209 | 32,230 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock, 5,000,000 shares authorized at March 31, 2026 and December 31, 2025: | ||||||||
| Series X non-voting convertible preferred stock, | 2,151 | 2,151 | ||||||
| Series X1 non-voting convertible preferred stock, | 53,543 | 53,543 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock, | 76 | 75 | ||||||
| Additional paid-in capital | 484,988 | 482,189 | ||||||
| Accumulated other comprehensive income (loss) | (72 | ) | 24 | |||||
| Accumulated deficit | (440,228 | ) | (401,203 | ) | ||||
| Total stockholders’ equity | 44,764 | 81,085 | ||||||
| Total liabilities, convertible preferred stock and stockholders’ equity | $ | 146,667 | $ | 169,009 | ||||
| ELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) | ||||||||
| For the Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses | ||||||||
| Research and development | $ | 17,197 | $ | 13,531 | ||||
| General and administrative | 3,984 | 4,433 | ||||||
| Total operating expenses | 21,181 | 17,964 | ||||||
| Loss from operations | (21,181 | ) | (17,964 | ) | ||||
| Other income, net | 1,118 | 1,409 | ||||||
| Change in fair value of warrant liabilities | (18,962 | ) | 10,060 | |||||
| Net loss | $ | (39,025 | ) | $ | (6,495 | ) | ||
| Other comprehensive loss: | ||||||||
| Unrealized loss on available-for-sale securities, net | (96 | ) | (44 | ) | ||||
| Comprehensive loss | $ | (39,121 | ) | $ | (6,539 | ) | ||
| Basic and diluted earnings per share of common stock | $ | (0.33 | ) | $ | (0.08 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 112,424,211 | 77,126,763 | ||||||
| Basic and diluted earnings per share of Series X and Series X1non-voting convertible preferred stock | $ | (18.25 | ) | $ | (4.32 | ) | ||
| Weighted-average shares outstanding of Series X and Series X1non-voting convertible preferred stock, basic and diluted | 114,508 | 114,508 | ||||||
